Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: A case-control study in Taiwan

Oncology Reports

Volumn 12, Issue 5, 2004, Pages 1045-1051

  Wu, Chi Ming ^a   Tang, Reiping ^b   Chen, Jim Ray ^b   Wu, Meng Chih ^b   Chien, Huei Tzu ^a   Changchien, Chung Rong ^b   Hsieh, Ling Ling ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Colorectal cancer; p53 antibody; p53 mutation; p53 protein accumulation

Indexed keywords

CANCER ANTIBODY; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; COLORECTAL TUMOR; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN TERTIARY STRUCTURE; SINGLE STRAND CONFORMATION POLYMORPHISM; TAIWAN; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CONSERVED SEQUENCE; DNA MUTATIONAL ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, P53; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN STRUCTURE, TERTIARY; TAIWAN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 16544392148     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.5.1045     Document Type: Article

References (25)

1. Hollstein M, Shomer B, Greeenblatt M, Sossi T, Hovig E, Montesano R and Harris CC. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 24: 141-146, 1996. (Pubitemid 26085752)
2. Beround C and Soussi T: p53 gene mutation: software and database. Nucleic Acids Res 26: 200-204, 1998.
3. Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG and Harris CC: Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 187: 8-18, 1999. (Pubitemid 29009831)
4. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC and Hainaut P: The IARC TP53 Database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614, 2002. (Pubitemid 34556481)
5. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA and Bunting PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58: 480-487, 1994. (Pubitemid 24268085)
6. Soussi T: p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60: 1777-1788, 2000.
7. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP: Development of antibodies against p53 in lung cancer patients appears to dependent on the type of p53 mutation. Cancer 52: 4168-4174, 1992.
8. Wild CP, Ridanpaa M, Anttila S, Lubin R, Soussi T, Vainio H and Husgafvel-Pursiain K: p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumor tissue. Int J Cancer 64: 176-181, 1995.
9. Davidoff AM, Iglehart JD and Marks JR: Immune respone to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89: 3439-3442, 1992.
10. Kaur J, Srivastava A and Ralhan R: Serum p53 antibodies in patients with oral lesions: Correlation with p53/HSP70 complexes. Int J Cancer 74: 609-613, 1997. (Pubitemid 28037503)
11. Forslund A, Kressner U, Lindmark G, Inganas M and Lundholm K: Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas. Int J Oncol 19: 501-506, 2001.
12. Angelopoulou K, Yu H, Bharaj B, Giai M and Diamandis EP: p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clin Biochem 33: 53-62, 2000. (Pubitemid 30313044)
13. Ralhan R, Arora S, Chattopadhyay TK, Shukla NK and Mathur M: Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer 85: 791-795, 2000. (Pubitemid 30131467)
14. Tang R, Ko MC, Wang JY, Changchien CR, Chen HH, Chen JS, Hsu KC, Chiang J M and Hsieh LL: Humoral response to p53 in human colorectal tumors: a prospective study of 1209 patients. Int J Cancer 94: 859-863, 2001. (Pubitemid 33032835)
15. Tang R, Wang PF, Wang HC, Wang JY and Hsieh LL: Mutations of p53 gene in humam colorectal cancer: distinct frameshifts among populations. Int J Cancer 91: 863-868, 2001. (Pubitemid 32178658)
16. Costa A, Marasca R, Valentinis B, Savarino M, Faranda A, Silvestrini R and Torelli G: p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 176: 45-53, 1995.
17. Bosari S, Viale G, Roncalli M, Graziani D, Borsani G, Lee AK and Coggi G: p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 147: 790-798, 1995.
18. El-Mahdani N, Vaillant JC, Guiguet M, Prevot S, Bertrand V, Bernard C, Pare R, Bereziat G and Hermelin B: Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. Br J Cancer 75: 528-536, 1997. (Pubitemid 27085294)
19. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A and Soussi T: Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 69: 809-816, 1994. (Pubitemid 24140657)
20. Hammel P, Leroy-Viard K, Chaumette MT, Villaudy J, Falzone C, Rouillard D, Hamelin R, Boissier B and Remvikos Y: Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer 81: 712-718, 1999. (Pubitemid 29214378)
21. von Brevern MC, Hollstein MC, Cawley HM, De Benedetti VM, Bennett WP, Liang L, He AG, Zhu SM, Tursz T, Janin N and Trivers GE: Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 56: 4917-4921, 1996. (Pubitemid 26374429)
22. Milner J: DNA damage, p53 and anticancer therapies. Nat Med 1:879-880,1995.
23. Wiedenfeld EA, Fernandez-Vina M, Berzofsky JA and Carbone DP: Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. Cancer Res 54: 1175-1177, 1994. (Pubitemid 24108053)
24. Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, Song Y, Appella E, Whiteside TL and DeLeo AB: A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin Cancer Res 6: 979-986 2000. (Pubitemid 30159357)
25. Ferries E, Connan F, Pages F, Gaston J, Hagnere AM, Vieillefond A, Thiounn N, Guillet JG and Choppin J: Identification of p53 peptides recognized by CD8+ T lymphocytes from patients with bladder cancer. Hum Immunol 62: 791-798, 2001. (Pubitemid 32703346)